Watson beefs up women's health biz, adds reps

Share this article:

Generics and specialty pharma Watson acquired a progesterone gel, marketed as Crinone and Prochieve, and added roughly 19 reps to its women's health sales force. Watson now employs close to 400 reps, according to Charlie Mayr, a company spokesperson.

The 19 new reps supporting Crinone and Prochieve were transitioned over from Columbia Laboratories, where Crinone and Prochieve were first introduced in 1997. Reps will target urologists, Ob/Gyns, reproductive endocrinologists and general practitioners, said Mayr, as well as institutions and clinics. Watson paid $47 million for exclusive US marketing rights, and received 11,200,000 shares of common stock in Columbia Laboratories as part of the deal. Merck Serono holds commercialization rights to Crinone in all markets outside of the US.

Mayr said Watson is looking to grow its branded drug portfolio, specifically in urology and women's health. Last February Watson became a marketing partner on HRA Pharma's Ella (ulipristal acetate), an emergency contraceptive currently undergoing FDA review; an FDA panel voted unanimously in favor of approval in mid-June. Ella (called EllaOne in Europe) received marketing approval across the European Union in May 2009, becoming the first product specifically designed for emergency contraceptive to be approved by the European Commission, according to an HRA Pharma statement.                 

A selective progesterone receptor modulator, Ella has demonstrated an ability in clinical trials to reduce the chance of pregnancy for up to five days after unprotected sex; Plan B is indicated as an emergency contraceptive for up to 72 hours, or three days, after sex, and lost sales in 2009 due to generic competition, according to a Teva financial statement. Watson launched a bioequivalent two-pill generic of Plan B, called Next Choice, in August of 2009.      

Mayr said he expects an FDA decision on Ella in “late July or early August.” Erin Gainer, CEO of HRA Pharma, told Agence France-Presse in June that a US approval could bring in sales of “several hundred million dollars.”   

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...